Trials / Active Not Recruiting
Active Not RecruitingNCT06764303
A Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
A Multicenter, Randomized, Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of NTQ5082 Capsules in the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
NTQ5082 capsule is a small molecule CFB factor inhibitor. This study is a multicenter, randomized, open label phase II clinical trial aimed at evaluating the efficacy, safety, and PK/PD characteristics of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NTQ5082 100mg qd | NTQ5082 100mg qd |
| DRUG | NTQ5082 200mg qd | NTQ5082 200mg qd |
Timeline
- Start date
- 2025-01-23
- Primary completion
- 2025-07-08
- Completion
- 2027-07-08
- First posted
- 2025-01-08
- Last updated
- 2025-09-23
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06764303. Inclusion in this directory is not an endorsement.